



<b>Body System:</b> <span style="color: red;">Cardiovascular</span>		
<b>Session Topic:</b> <span style="color: blue;">Cardiovascular Pharmacology</span>		
<b>Educational Format</b>		<b>Faculty Expertise Required</b>
<b>REQUIRED</b>	Interactive Lecture	Expertise in the field of study. Experience teaching in the field of study is desired. Preferred experience with audience response systems (ARS). Utilizing polling questions and engaging the learners in Q&A during the final 15 minutes of the session are required.
<b>OPTIONAL</b>	Problem-Based Learning (PBL)	Expertise teaching highly interactive, small group learning environments. Case-based, with experience developing and teaching case scenarios for simulation labs preferred. Other workshop-oriented designs may be accommodated. A typical PBL room is set for 50-100 participants, with 7-8 each per round table. <u>Please describe your interest and plan for teaching a PBL on your proposal form.</u>
<b>Professional Practice Gap</b>	<b>Learning Objective(s) that will close the gap and meet the need</b>	<b>Outcome Being Measured</b>
<ul style="list-style-type: none"> <li>• Preventable cardiovascular medication errors are common in the US</li> <li>• Preventable medication errors are higher with regard to look-alike or sound-alike names, omission, dosing, dispensing, and timing</li> <li>• Communication failures and poor care coordination are major sources of medication errors for patients with acute stroke</li> <li>• Physicians are frequently non-adherent to cardiovascular practice guidelines</li> <li>• Patients frequently exhibit poor medication adherence</li> </ul>	<ol style="list-style-type: none"> <li>1. Establish protocols for the consistent application of current practice guidelines for the treatment of common cardiovascular conditions.</li> <li>2. Determine when a patient’s medication history or overall health may produce severe side effects or interfere with treatment for a cardiovascular condition.</li> <li>3. Develop a collaborative treatment plan for common cardiovascular conditions, emphasizing medication adherence and monitoring.</li> <li>4. Design a care coordination and communication plan with all members of the cardiovascular care team.</li> </ol>	Learners will submit written commitment to change statements on the session evaluation, indicating how they plan to implement presented practice recommendations.
<b>ACGME Core Competencies Addressed</b> (select all that apply)		
X	Medical Knowledge	Patient Care
X	Interpersonal and Communication Skills	Practice-Based Learning and Improvement
	Professionalism	Systems-Based Practice
<b>Faculty Instructional Goals</b>		
Faculty play a vital role in assisting the AAFP to achieve its mission by providing high-quality, innovative education for physicians, residents and medical students that will encompass the art, science, evidence and socio-economics of family medicine and to support		



the pursuit of lifelong learning. By achieving the instructional goals provided, faculty will facilitate the application of new knowledge and skills gained by learners to practice, so that they may optimize care provided to their patients.

- Provide up to 3 evidence-based recommended practice changes that can be immediately implemented, at the conclusion of the session; including SORT taxonomy & reference citations
- Facilitate learner engagement during the session
- Address related practice barriers to foster optimal patient management
- Provide recommended journal resources and tools, during the session, from the American Family Physician (AFP), Family Practice Management (FPM), and Familydoctor.org patient resources; those listed in the References section below are a good place to start
  - Visit <http://www.aafp.org/journals> for additional resources
  - Visit <http://familydoctor.org> for patient education and resources
- Provide recommendations for establishing protocols for the consistent application of current practice guidelines for the treatment of common cardiovascular conditions.
- Provide recommendations for determining when a patient's medication history or overall health may produce severe side effects or interfere with treatment for a cardiovascular condition.
- Provide strategies and resources for developing a collaborative treatment plan for common cardiovascular conditions, emphasizing medication adherence and monitoring.
- Provide strategies and resources for designing a care coordination and communication plan with all members of the cardiovascular care team.
- Provide recommendations regarding new FDA approved medications for the treatment of a variety of cardiology/vascular diseases; including safety, efficacy, tolerance, and cost considerations relative to currently available options.
- Provide recommendations regarding guidelines for Medicare reimbursement.
- Provide recommendations to maximize office efficiency and guideline adherence to the diagnosis and management of
- Provide instructions regarding the incorporation and use of the PCMH/ACO/Primary Care Core Measure Set into practice.

### Needs Assessment

Of the 214 million office visits to general and family practitioners in the United States in 2010, medications for cardiovascular issues were among the top 5 most prescribed during 85% of those office visits.<sup>1</sup> Many recent reports on patient safety suggest that as many as half of patients suffering acute myocardial infarctions fail to receive aspirin and  $\beta$ -blockers, and thromboprophylaxis with oral anticoagulants is often underutilized in treating patients with atrial fibrillation, due to errors of omission that could cost more lives and cause more disability than errors resulting from negligent practice.<sup>2-4</sup> In addition, of the 450,000 preventable medication-related adverse events that occur each year in the US, cardiovascular medications prescribed to inpatients account a large portion of those errors, averaging one medication error per day.<sup>5</sup> In general, errors are higher with regard to medications with look-alike or sound-alike names, but



medication dosing, dispensing, and timing errors are also common; more specifically common medication errors for:<sup>5,6</sup>

- Patients with acute coronary syndrome (ACS) – dosing, omission (initial treatment or resuming treatment), and miscalculation of a patient’s weight.
  - Non-optimal dosing of antiplatelet agents
  - Incorrect dosing of fibrinolytic agents
  - Incorrect dosing of anticoagulant agents
- Omission medication errors involving statins
- Patients with acute heart failure are prone to polypharmacy and associated issues with dosing, timing, and drug-drug interactions
- Communication failures and poor care coordination are major sources of medication errors for patients with acute stroke
- Nonadherence to practice guidelines

Data from a recent American Academy of Family Physicians (AAFP) CME Needs Assessment survey indicate that family physicians have knowledge gaps with regard to optimal cardiovascular pharmacological management.<sup>7</sup> More specifically, CME outcomes data from 2012-13, and 2015-16 AAFP FMX (formerly Assembly): *Cardiovascular Pharmacology* sessions suggest that physicians have knowledge and practice gaps with regard to appropriate use of ACE in first line treatment; appropriate and earlier use of beta-blockers; use of a care coordinator for post discharge; more appropriate use of staging criteria; consistent adherence to guidelines; effectively counseling patients to foster medication adherence; and more effective use of atenolol, metoprolol, and spironolactone generally.<sup>8-11</sup>

Several factors may contribute to suboptimal use of antiplatelet therapies, including lack of awareness or familiarity with guidelines, complex guidelines, complex medical regimens, poor coordination of care with cardiologists, and lack of knowledge and skills to use adherence-improving tools or resources with their staff or patients.<sup>6,12-14</sup> A recent review of the literature suggests that nonsteroidal anti-inflammatory drug (NSAID) use is associated with increased risk of bleeding and cardiovascular disease in patients receiving antithrombotic therapy.<sup>15,16</sup> Additionally, recent research suggests that testosterone injectables may be associated with an increase in cardiovascular risk.<sup>17-19</sup>

A recent review of the literature reveals the following cardiovascular pharmacology updates:<sup>20-22</sup>

- Oral beta blockers should be started within 24 hours of presentation of acute coronary syndrome, if there are no contraindications.
- Treatment with ACE inhibitors is recommended in persons with a left ventricular ejection fraction less than 0.40, hypertension, diabetes mellitus, or stable chronic kidney disease.
- Chewable aspirin without an enteric coating, at a dose of 162 to 325 mg, should be administered as soon as possible to patients presenting with symptoms suggestive of acute coronary syndrome.
- Dual antiplatelet therapy with ticagrelor or clopidogrel in combination with aspirin should be given for up to one year in the invasive and ischemia-guided treatment approaches to ST elevation myocardial infarction and non-ST elevation acute coronary syndrome.



- Patients taking warfarin (Coumadin) should be treated using systematic processes of care to optimize effectiveness and minimize adverse effects. Health care professionals skilled in the initiation and assessment of therapy and dosing adjustments can dramatically influence outcomes.
- In patients with atrial fibrillation and at least one other risk factor for stroke, direct oral anticoagulants (e.g. dabigatran, rivaroxaban, apixaban, and edoxaban) that do not require frequent laboratory monitoring are as effective as warfarin for prevention of stroke or systemic embolism and have comparable risks of major bleeding.
- Compared with usual clinic-based care, patient self-testing for international normalized ratios, with or without self-dosing of warfarin, is associated with significantly fewer deaths and thromboembolic complications without any increase in bleeding complications for a selected group of motivated patients who have completed appropriate training.

The U.S. Food and Drug Administration (FDA) has approved a number of new drugs in recent years for the treatment of a variety of cardiology/vascular diseases.<sup>23</sup> Physicians need to be kept up to date on new treatment options, including safety, efficacy, tolerance, and cost considerations relative to currently available options. Examples from the last five years include, but are not limited to the following:<sup>23</sup>

- **Drugs Approved in 2017**
  - Bevyxxa (betrixaban); Portola Pharmaceuticals; For the the prophylaxis of venous thromboembolism, Approved June 2017
- **Drugs Approved in 2016**
  - Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
  - Yosprala (aspirin and omeprazole); Aralez Pharmaceuticals; For the prevention of cardiovascular and cerebrovascular events, Approved September 2016
- **Drugs Approved in 2015**
  - Corlanor (ivabradine); Amgen; For the treatment of chronic heart failure, Approved April 2015
  - Entresto (sacubitril and valsartan); Novartis; For the treatment of chronic heart failure, Approved July 2015
  - Kanuma (sebelipase alfa); Alexion; For the treatment of Lysosomal Acid Lipase (LAL) deficiency, Approved December 2015
  - Kengreal (cangrelor) ; The Medicines Company; For reducing periprocedural thrombotic events, Approved June 2015
  - Praluent (alirocumab); Sanofi Aventis; For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, Approved July 2015
  - Prestalia (perindopril arginine and amlodipine besylate); Symplmed Pharmaceuticals; For the treatment of hypertension, Approved January 2015
  - Repatha (evolocumab) ; Amgen; For the treatment of high cholesterol, Approved August 2015
  - Savaysa (edoxaban); Daiichi Sankyo; For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015



- Uptravi (selexipag); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved December 2015
- **Drugs Approved in 2014**
  - Epanova (omega-3-carboxylic acids); AstraZeneca; For the treatment of severe hypertriglyceridemia, Approved May 2014
  - Zontivity (vorapaxar); Merck; For the reduction of thrombotic cardiovascular events, Approved May 2014
- **Drugs Approved in 2013**
  - Adempas (riociguat); Bayer Healthcare Pharmaceuticals; For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension, Approved October 2013
  - Kynamro (mipomersen sodium); Genzyme; For the treatment of homozygous familial hypercholesterolemia, Approved January 2013
  - Liptruzet (ezetimibe and atorvastatin); Merck; For the treatment of hyperlipidemia, Approved May 2013
  - Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013
  - Opsumit (macitentan); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved October 2013
  - Varithena (polidocanol injectable foam); BTG plc; For the treatment of varicose veins, November 2013
- **Drugs Approved in 2012**
  - Eliquis (apixaban); Bristol-Myers Squibb; For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation, Approved December 2012
  - Juxtapid (lomitapide); Aegerion Pharmaceuticals; For the treatment of homozygous familial hypercholesterolemia, Approved December of 2012
  - Vascepa (icosapent ethyl); Amarin Pharmaceuticals; For the treatment of hypertriglyceridemia, Approved July of 2012
- **Drugs Approved in 2011**
  - Brilinta (ticagrelor); AstraZeneca; For the reduction of thrombotic events in patients with acute coronary syndrome, Approved July 2011
  - Edarbi (azilsartan medoxomil); Takeda; For the treatment of hypertension, Approved February 2011
  - Edarbyclor (azilsartan medoxomil and chlorthalidone); Takeda; For the treatment of hypertension, Approved December of 2011
  - Xarelto (rivaroxaban); Bayer; For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011
  - Xarelto (rivaroxaban); Janssen Pharmaceuticals; For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011
- **Drugs Approved in 2010**
  - Amturnide (aliskiren + amlodipine + hydrochlorothiazide); Novartis; For the treatment of uncontrolled hypertension, Approved December 2010
  - Pradaxa (dabigatran etexilate mesylate); Boehringer Ingelheim; For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010



- Tekamlo (aliskiren + amlodipine); Novartis; For the treatment of hypertension, Approved August 2010
- Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide); Daiichi Sankyo; For the treatment of hypertension, Approved July 2010

In addition to physician and systems related factors of cardiovascular medication errors, nearly half of the 187 million patients in the US do not take their medications as prescribed, primarily due to poor medication adherence.<sup>24</sup> Identified barriers to medication nonadherence include:<sup>24-28</sup>

- Fragmentation across the health care system, which can limit care coordination or make it difficult for physicians to easily access patient information across different care settings.
- The complexity of the drug therapies, which may lead to a patient's perceived fear of side effects from the medication(s) or general confusion about the regimen.
- Poor communication between a provider and a patient about the medications, or difficulty explaining and understanding the benefits and adverse effects of complex drug therapies.
- Unintentional patient behavioral factors, such as forgetfulness.
- Patients' physical or cognitive impairments.
- Socioeconomic factors, such as low health literacy, and high medication costs, as well as lack of transportation to fill their prescriptions at a pharmacy.
- Newly diagnosed, older heart failure patients with comorbid conditions, polypharmacy, and poor sleep.

Physicians can improve medication adherence by:<sup>29-37</sup>

- Asking if the patient has been taking medications as prescribed.
- Developing a differential diagnosis of nonadherence.
- Tailor the solution to the problem (i.e. adherence solution for a nonadherence problem)
- Prescribe the right drug at the right dose
- Involving the entire care team with medication adherence
- Provide health coaching for patients with chronic conditions
- Develop collaborative care plans
- Integrating a behavioral health specialist into practice
- Use motivational interviewing to encourage patients to change unhealthy behaviors

Physicians can improve patient satisfaction with the referral process by using readily available strategies and tools such as, improving internal office communication, engaging patients in scheduling, facilitating the appointment, tracking referral results, analyzing data for improvement opportunities, and gathering patient feedback.<sup>38,39</sup>

Physicians may improve the efficacy of prescribed cardiovascular medications by engaging in continuing medical education that provides practical integration of current evidence-based guideline-directed medical therapy into their standards of care, including, but not limited to the following the joint guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA).<sup>40</sup>

The American Academy of Family Physicians Academy has participated in the Core Measures Collaborative (the Collaborative) convened by America's Health Insurance Plans (AHIP) since



August 2014. The Collaborative is a multi-stakeholder effort working to define core measure sets of various specialties promoting alignment and harmonization of measure use and collection across both public and private payers.

Participants in the Collaborative included Centers for Medicare and Medicaid Services (CMS), the National Quality Forum (NQF), private payers, provider organizations, employers, and patient and consumer groups. This effort exists to decrease physician burden by reducing variability in measure selection, specifications and implementation—making quality measurement more useful and meaningful for consumers, employers, as well as public and private clinicians.

With significant AAFP input, a PCMH/ACO/Primary Care Core Measure Set has been developed for primary care. The goal of this set is to decrease burden and allow for more congruence between payer reporting programs.<sup>41</sup>

Resources: Evidence-Based Practice Recommendations/Guidelines/Performance Measures

- ACC/AHA Joint Guidelines<sup>20,40</sup>
- American College of Chest Physicians (ACCP) 2016 guidelines on antithrombotic therapy for venous thromboembolic (VTE) disease<sup>42</sup>
- NICE: Medicines adherence. Involving patients in decisions about prescribed medicines and supporting adherence<sup>43</sup>
- Coronary Artery Disease/Coronary Heart Disease. AFP Journal collection<sup>44</sup>
- Atrial Fibrillation. AFP Journal Collection<sup>45</sup>
- Heart Failure. AFP Journal Collection<sup>46</sup>
- Hypertension. AFP Journal Collection<sup>47</sup>
- Updated Guidelines on Outpatient Anticoagulation<sup>22</sup>
- Medication adherence: we didn't ask and they didn't tell<sup>29</sup>
- Health Coaching: Teaching Patients to Fish<sup>30</sup>
- An organized approach to chronic disease care<sup>48</sup>
- The integrated summary: a documentation tool to improve patient care.<sup>49</sup>
- Engaging Patients in Collaborative Care Plans<sup>31</sup>
- Encouraging patients to change unhealthy behaviors with motivational interviewing<sup>33</sup>
- Envisioning new roles for medical assistants: strategies from patient-centered medical homes<sup>34</sup>
- Health coaching for patients with chronic illness<sup>35</sup>
- Adding health education specialists to your practice<sup>36</sup>
- Improving anticoagulation management at the point of care<sup>37</sup>
- Simple tools to increase patient satisfaction with the referral process<sup>38</sup>
- FamilyDoctor.org. High Blood Pressure | Overview (patient education)<sup>50</sup>
- FamilyDoctor.org. Arrhythmia | Overview (patient education)<sup>51</sup>
- FamilyDoctor.org. Heart Failure | Overview (patient education)<sup>52</sup>
- FamilyDoctor.org. Deep Vein Thrombosis | Treatment (patient education)<sup>53</sup>
- FamilyDoctor.org. Caregiving: Caring for an Elderly Relative - Managing Medicines (patient education)<sup>54</sup>



- FamilyDoctor.org. Seniors: Managing Your Medications (patient education)<sup>55</sup>
- FamilyDoctor.org. Working With Your Doctor (patient education)<sup>56</sup>
- FamilyDoctor.org. Prescription Medicines (patient education)<sup>57</sup>

#### References

1. Centers for Disease Control and Prevention (CDC). National Ambulatory Medical Care Survey. In: Ambulatory and Hospital Care Statistics Branch, ed2010.
2. Rosenman MB, Baker L, Jing Y, et al. Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. *Current medical research and opinion*. 2012;28(9):1407-1414.
3. Tierney WM, Overhage JM, Murray MD, et al. Effects of computerized guidelines for managing heart disease in primary care. *Journal of general internal medicine*. 2003;18(12):967-976.
4. Deitelzweig S. Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. *The Ochsner journal*. 2013;13(3):419-427.
5. Michaels AD, Spinler SA, Leeper B, et al. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. *Circulation*. 2010;121(14):1664-1682.
6. Bird GC, Cannon CP, Kennison RH. Results of a survey assessing provider beliefs of adherence barriers to antiplatelet medications. *Critical pathways in cardiology*. 2011;10(3):134-141.
7. AAFP. 2012 CME Needs Assessment: Clinical Topics. American Academy of Family Physicians; 2012.
8. American Academy of Family Physicians (AAFP). AAFP FMX CME Outcomes Report. Leawood KS: AAFP; 2016.
9. American Academy of Family Physicians (AAFP). 2012 AAFP Scientific Assembly: CME Outcomes Report. Leawood KS: AAFP; 2012.
10. American Academy of Family Physicians (AAFP). 2013 AAFP Scientific Assembly: CME Outcomes Report. Leawood KS: AAFP; 2013.
11. American Academy of Family Physicians (AAFP). AAFP FMX CME Outcomes Report. Leawood KS: AAFP; 2015.
12. Faxon D, Brown M. Antiplatelet therapy for postdischarge medical management of acute coronary syndrome. *The American journal of medicine*. 2008;121(3):171-178.
13. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. *Journal of the American College of Cardiology*. 2003;41(1):56-61.
14. Pearson TA, McBride PE, Miller NH, Smith SC. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. *Journal of the American College of Cardiology*. 1996;27(5):1039-1047.
15. Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. *JAMA : the journal of the American Medical Association*. 2015;313(8):805-814.
16. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation



- receiving antithrombotic therapy: a nationwide cohort study. *Annals of internal medicine*. 2014;161(10):690-698.
17. Layton JB, Meier CR, Sharpless JL, Sturmer T, Jick SS, Brookhart MA. Comparative Safety of Testosterone Dosage Forms. *JAMA internal medicine*. 2015;175(7):1187-1196.
  18. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. *JAMA : the journal of the American Medical Association*. 2013;310(17):1829-1836.
  19. U.S. Food and Drug Administration. Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke. *MedWatch* 2015;
  20. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130(25):e344-426.
  21. Hauk L. Management of Non-ST Elevation Acute Coronary Syndrome: A Guideline from the AHA and ACC. *American family physician*. 2015;92(2):151-153.
  22. Wigle P, Hein B, Bloomfield HE, Tubb M, Doherty M. Updated guidelines on outpatient anticoagulation. *American family physician*. 2013;87(8):556-566.
  23. CenterWatch. FDA Approved Drugs by Medical Condition. 2017;
  24. American Heart Association, American Stroke Association. A Tough Pill to Swallow: Medication Adherence and Cardiovascular Disease. *FACT SHEET*. 2014.
  25. Arnold CL, Coran JJ, Hagen MG. Revisiting patient communication training: An updated needs assessment and the AGENDA model. *Patient education and counseling*. 2012.
  26. Doroodchi H, Abdolrasulnia M, Foster JA, et al. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. *BMC family practice*. 2008;9:42.
  27. Goodyear-Smith F, Kenealy T, Wells S, Arroll B, Horsburgh M. Patients' preferences for ways to communicate benefits of cardiovascular medication. *Annals of family medicine*. 2011;9(2):121-127.
  28. Knafl GJ, Riegel B. What puts heart failure patients at risk for poor medication adherence? *Patient preference and adherence*. 2014;8:1007-1018.
  29. Brown M, Sinsky CA. Medication adherence: we didn't ask and they didn't tell. *Family practice management*. 2013;20(2):25-30.
  30. Ghorob A. Health Coaching: Teaching Patients to Fish. *Family practice management*. 2013;20(3):40-42.
  31. Mauksch L, Safford B. Engaging Patients in Collaborative Care Plans. *Family practice management*. 2013;20(3):35-39.
  32. Sinsky TA, Sinsky CA. A streamlined approach to prescription management. *Family practice management*. 2012;19(6):11-13.
  33. Stewart EE, Fox CH. Encouraging patients to change unhealthy behaviors with motivational interviewing. *Family practice management*. 2011;18(3):21-25.
  34. Naughton D, Adelman AM, Bricker P, Miller-Day M, Gabbay R. Envisioning new roles for medical assistants: strategies from patient-centered medical homes. *Family practice management*. 2013;20(2):7-12.



35. Bennett HD, Coleman EA, Parry C, Bodenheimer T, Chen EH. Health coaching for patients with chronic illness. *Family practice management*. 2010;17(5):24-29.
36. Chambliss ML, Lineberry S, Evans WM, Bibeau DL. Adding health education specialists to your practice. *Family practice management*. 2014;21(2):10-15.
37. Caffee AE, Teichman PG. Improving anticoagulation management at the point of care. *Family practice management*. 2002;9(2):35-37.
38. Jarve RK, Dool DW. Simple tools to increase patient satisfaction with the referral process. *Family practice management*. 2011;18(6):9-14.
39. American Academy of Family Physicians (AAFP). FPM Toolbox: Referral Management. 2013;
40. American Heart Association. ACC/AHA Joint Guidelines. 2014;
41. American Academy of Family Physicians (AAFP). PCMH/ACO/Primary Care Core Measure Set. 2016;
42. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest*. 2016;149(2):315-352.
43. National Guideline Clearinghouse. Medicines adherence. Involving patients in decisions about prescribed medicines and supporting adherence. 2009;
44. American Academy of Family Physicians (AAFP). Coronary Artery Disease/Coronary Heart Disease. *AFP Journal collection* 2014;
45. American Academy of Family Physicians (AAFP). Atrial Fibrillation. *AFP Journal Collection* 2014;
46. American Academy of Family Physicians (AAFP). Heart Failure. *AFP Journal Collection* 2014;
47. American Academy of Family Physicians (AAFP). Hypertension. *AFP Journal Collection* 2013;
48. Lyon RK, Slawson J. An organized approach to chronic disease care. *Family practice management*. 2011;18(3):27-31.
49. Stelman MA. The integrated summary: a documentation tool to improve patient care. *Family practice management*. 2003;10(4):33-39.
50. FamilyDoctor.org. High Blood Pressure | Overview. 1996;
51. FamilyDoctor.org. Arrhythmia | Overview 2000;
52. FamilyDoctor.org. Heart Failure | Overview. 2000;
53. FamilyDoctor.org. Deep Vein Thrombosis | Treatment. 2004;
54. FamilyDoctor.org. Caregiving: Caring for an Elderly Relative - Managing Medicines. 2012;
55. FamilyDoctor.org. Seniors: Managing Your Medications. 2013;
56. FamilyDoctor.org. Working With Your Doctor. 2013;
57. FamilyDoctor.org. Prescription Medicines. 2013;